InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Outlook Therapeutics, Inc.

OTLK Clue Score30
United States Fiscal year ends September CIK 0001649989
$0.60 +6.19% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.60 −72.78% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2017Revenue3.8Operating income−35.9Net income−38.8EPS, diluted−1.80Fiscal year 2018Revenue3.1 −19.0%Operating income−29.6Net income−30.1EPS, diluted−1.22Fiscal year 2019Revenue8.1 +163.8%Operating income−36.3Net income−34.5Fiscal year 2020Operating income−36.8Net income−35.2EPS, diluted−0.67Fiscal year 2021Operating income−51.7Net income−53.2EPS, diluted−0.35Fiscal year 2022Operating income−63.1Net income−66.1EPS, diluted−0.31Fiscal year 2023Operating income−53.1Net income−59.0EPS, diluted−4.72Fiscal year 2024Operating income−71.7Net income−75.4EPS, diluted−4.06Fiscal year 2025Revenue1.4Operating income−67.1Net income−62.4EPS, diluted−1.79
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 3.8 3.1 8.1 n/a n/a n/a n/a n/a 1.4
Growth −19.0% +163.8%
Operating income −35.9 −29.6 −36.3 −36.8 −51.7 −63.1 −53.1 −71.7 −67.1
Net income −38.8 −30.1 −34.5 −35.2 −53.2 −66.1 −59.0 −75.4 −62.4
Growth
EPS, diluted −1.80 −1.22 n/a −0.67 −0.35 −0.31 −4.72 −4.06 −1.79

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2017Operating margin−941.4%Net margin−1,019.3%Free cash flow margin−414.5%Fiscal year 2018Operating margin−960.1%Net margin−974.6%Free cash flow margin−1,160.2%Fiscal year 2019Operating margin−445.6%Net margin−423.8%Free cash flow margin−401.8%Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Fiscal year 2025Gross margin4.0%Operating margin−4,744.3%Net margin−4,416.2%
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Gross margin n/a n/a n/a n/a n/a n/a n/a n/a 4.0%
Operating margin −941.4% −960.1% −445.6% n/a n/a n/a n/a n/a −4,744.3%
Net margin −1,019.3% −974.6% −423.8% n/a n/a n/a n/a n/a −4,416.2%
Free cash flow margin −414.5% −1,160.2% −401.8% n/a n/a n/a n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−15.5Capital expenditure−0.3Free cash flow−15.8Fiscal year 2018Operating cash flow−33.0Capital expenditure−2.8Free cash flow−35.8Fiscal year 2019Operating cash flow−32.3Capital expenditure−0.4Free cash flow−32.7Fiscal year 2020Operating cash flow−31.8Fiscal year 2021Operating cash flow−54.3Fiscal year 2022Operating cash flow−56.7Fiscal year 2023Operating cash flow−43.0Fiscal year 2024Operating cash flow−68.8Fiscal year 2025Operating cash flow−51.8
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −15.5 −33.0 −32.3 −31.8 −54.3 −56.7 −43.0 −68.8 −51.8
Capital expenditure −0.3 −2.8 −0.4 n/a n/a n/a n/a n/a n/a
Free cash flow −15.8 −35.8 −32.7 n/a n/a n/a n/a n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2017Cash3.2Total debt0.2Net cash (debt)3.0Shareholders’ equity−33.7Fiscal year 2018Cash1.7Total debt0.2Net cash (debt)1.6Shareholders’ equity−25.5Fiscal year 2019Cash8.0Total debt1.1Net cash (debt)6.9Shareholders’ equity−16.1Fiscal year 2020Cash12.5Shareholders’ equity2.8Fiscal year 2021Cash14.5Shareholders’ equity4.6Fiscal year 2022Cash17.4Shareholders’ equity8.7Fiscal year 2023Cash23.4Shareholders’ equity−14.4Fiscal year 2024Cash14.9Shareholders’ equity−73.1Fiscal year 2025Cash8.1Shareholders’ equity−32.2
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 3.2 1.7 8.0 12.5 14.5 17.4 23.4 14.9 8.1
Total debt 0.2 0.2 1.1 n/a n/a n/a n/a n/a n/a
Net cash (debt) 3.0 1.6 6.9 n/a n/a n/a n/a n/a n/a
Shareholders’ equity −33.7 −25.5 −16.1 2.8 4.6 8.7 −14.4 −73.1 −32.2

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending September, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 30 Sep 2017 FY2018† 30 Sep 2018 FY2019 30 Sep 2019 FY2020† 30 Sep 2020 FY2021† 30 Sep 2021 FY2022 30 Sep 2022 FY2023† 30 Sep 2023 FY2024 30 Sep 2024 FY2025† 30 Sep 2025
Operations
−15.5 −33.0 −32.3 −31.8 −54.3 −56.7 −43.0 −68.8 −51.8
Growth
2.7 3.1 3.4 0.2 n/a n/a n/a n/a n/a
Investment
−0.3 −2.8 −0.4 n/a n/a n/a n/a n/a n/a
calc −15.8 −35.8 −32.7 n/a n/a n/a n/a n/a n/a
Growth
calc −0.66 −0.91 n/a n/a n/a n/a n/a n/a n/a
−0.3 −2.8 −0.4 −0.9 n/a n/a n/a n/a n/a
Financing
16.6 34.4 39.0 37.2 56.2 59.6 49.0 60.3 45.0

† The diluted share count jumps at 2018 and 2020 and 2021 and 2023 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Lines marked calc are worked out here from filed figures; point at one for how. Capital expenditure, dividends and buybacks are shown as money out, so negative.